Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by GRAMPS1996on Jul 14, 2018 10:00am
204 Views
Post# 28316089

Theralase CEO Roger White talks to Cantech Letter

Theralase CEO Roger White talks to Cantech Letter

What are your chances of getting Fast Track approval from the FDA? What about Breakthrough Status?

Fast Track and Breakthrough Status are defined by the FDA as “a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions (such as cancer) and fill an unmet medical need (no therapy exists or by providing a therapy which may be potentially better than available therapy).” Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition (cancer) and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). (Phase 1/2a clinical data). Based on these definitions, Theralase has a 99% chance of achieving Fast Track Status and after completion of a successful Phase 1/2a clinical trial over a 90% chance of achieving Breakthrough Status.

We are completing our preclinical work at Princess Margaret Cancer Centre and plan to use Princess Margaret as the lead Canadian site for the Phase 1/2a clinical trial.

Have you tested your four key compounds you developed over last 10 years in other cancers. If so, what were the results?

We have completed testing our four lead PDCs on a variety of cancers, such as brain, breast, colon, prostate, pancreatic and lung, in addition to bladder cancer, both in in-vitro models (Petri dish of cells) and small animal in-vivo models all with up to 100% cancer kill and virtually 0% toxicity.


Bullboard Posts